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1. Introduction 
In renal replacement therapy (RRT) a wide range of uremic toxins have to be removed 
(Vanholder et al., 2003; Vanholder et al., 2008). It is well known that the combination of 
diffusive and convective dialysis strategies (online hemodiafiltration, olHDF) improves the 
removal of uremic toxins, i.e. middle molecules, hydrophobic substances and protein 
(albumin) bound materials (Krieter et al., 2005; Ahrenholz et al., 2004; Ronco et al., 1999; 
Kim, 1994; Testa et al., 2006; Meyer et al., 2005; Mandolfo et al., 2006; Kanter et al., 2008). In 
the presence of  ultrapure dialysis fluid which is ultrafiltrated by endotoxin restraint 
systems (Weber et al., 2000; Canaud et al., 2001; Minetti et al., 1985; Hakim et al., 1984) and 
biocompatible high flux dialysis membranes the convective diffusive treatment significantly 
prevents the complement activation (Braun et al., 1995; Savica et al., 2006; Jorres et al, 1999; 
Hörl et al., 1986) in the first minutes of olHDF session and removes proinflammatory 
substances (cytokines) too (Bellomo et al., 1991; Filiopoulos et al., 2008; Haas et al., 2007; 
Libetta et al., 2007; Mariano et al., 2005). The intra and interdialytic inflammations are 
reduced (Ramirez et al., 2007; Ramirez et al., 2007; Carracedo et al., 2006).  The suppressed 
inflammatory process during olHDF leads to an increasing serum albumin concentration via 
an increased synthesis rate. In spite of a varying albumin removal caused by different 
dialysis membranes with/without adsorptive character and pore size (Pichaiwong et al., 
2006; Yamashita, 2007; Tomo et al., 2008; Winchester et al.,2003; Winchester et al., 2004) the 
albumin synthesis rate increases by absent inflammation (Giordano et al., 2001).  It is shown 
that in olHDF the ESA dosage needed to reach the hemoglobin goal is reduced (Vaslaki et 
al., 2006; Bonforte et al., 2002; Eiselt et al., 2000). The efficacy of dialysis measured by single 
pool Kt/V could be improved (Ahrenholz et al., 1997; Ding et al., 2002). There is evidence of 
longer survival of patients treated by olHDF versus hemodialysis (HD) independently of 
dialysis dosage (Canaud et al., 2008; Panicchi et al., 2008). The cycling of hemoglobin levels 
depends on inflammatory episodes and malnutrition (Del et al., 2005; Brimble et al., 2005). 
This retrospective, non randomized, multicentre, descriptive clinical evaluation examined 
the influence of olHDF on hemoglobin concentration (Hb), ESA dosage (ESA), Hb variability 
(Hbvar), albumin and CRP. 
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2. Materials and methods 
233 chronic hemodialysis patients were included in this clinical evaluation (dialysis center 1 
(D1) n= 94, D2 n= 35, D3 n= 104 patients). 54.9% were male; the mean age was 63.8 years 
(range 22 - 89).  The patients in all three centers were comparable with regard to gender 
distribution, mean age, mean time on dialysis, and distribution of underlying kidney 
disease.  The clinical evaluation was carried out for 12 months retrospectively. 
Laborchemical parameters were estimated for hemoglobin (Hb) every 2 weeks 
(labanalyzer), CRP (turbidometry), albumin (alb; nephelometry) and ferritin 
(chemiluminescence technique) every three months.  Serum iron (photometry) and 
transferrin (turbidometry) were necessary to calculate the transferrin saturation (every 4 
weeks). Single pool kt/V was evaluated every 3 months with the Daugirdas technique 
(Daugirdas, 1993). Intraindividual variability of hemoglobin (Hbvar) was defined as the 
difference between minimal and maximal concentration (range) and by time to reach the 
target between Hb 6.8 mmol/l and 8.0 mmol/l within 9 months. Relevant changes in ESA 
dosages were defined as an elevation greater than two fold and lowering of a half of the 
ESA dosage, the end of ESA application or the start with more than 4200 U/week. 
Hemodialysis (HD) was performed by MTS 5008 (Fresenius Medical Care), low flux dialyser 
FX8, FX10 (helixone, Fresenius Medical Care), QB 300 ml/min, QD 500 ml/min, ultrapure 
dialysis fluid, online hemodiafiltration (olHDF) by MTS 5008 (Fresenius Medical Care; 
automatic procedure with factor 1.2), high flux dialyser FX 60, FX80 (helixone, Fresenius 
Medical Care), QB 300 ml/min, QD 350…..360 ml/min, QS 51….60 ml/min, ultrapure 
dialysis fluid and Nikkiso DBB 05 (Nikkiso Medical Ltd.), high flux dialyser FDY 15 G 
(PEPA, Nikkiso Medical Ltd.), QB 300 ml/min, QD 700 ml/min, QS 60 ml/min, ultrapure 
dialysis fluid (QB… blood flow; QD…dialysate flow; Qs…substitution flow). The group 
“mixed” contained patients started with HD and switched to olHDF (at least 6 months 
olHDF). We compared the mean values of collected serum parameters three times a month. 
Descriptive statistical evaluation was calculated by mean, standard deviation and 
significance by Wilcoxon test, correlation by Spearman rang correlation. The level of 
significance was defined as p< 0.05. 
3. Results 
The distribution of ESA applications in the three observed dialysis centers can be seen in 
table 1. Totally 185 of 233 patients received at least one ESA dosage. The mean value of 
ferritin was 538 mg/L. The transferrin saturation (TSAT) did not differ significantly in the 
observed dialysis units.  
 
 
Dialysis unit 
Total 
1 2 3 
N % N % N % N % 
Application of ESA 
37 39.4 4 11.4 7 6.7 48 20.6 
without ESA 
At least 1 ESA dosage 57 60.6 31 88.6 97 93.3 185 79.4 
Table 1. Application of ESA per dialysis unit and overall. 
The mean weekly ESA dosage can be seen in table 2: 
www.intechopen.com
Influence of Online Hemodiafiltration on Hemoglobin Level,  
ESA-Dosage and Serum Albumin – A Retrospective, Multicenter Analysis 
 
163 
 
Dialysis unit  
Total 1 2 3 
All patients  N 94 35 104 233 
Mean 3550 5934 9177 6420 
SD 4443 5316 8487 7129 
Min 0 0 0 0 
Median 1577 5077 6500 4692 
Max 18667 26769 46538 46538 
Patients with at least one ESA dosage  N 57 31 97 185 
Mean 5855 6700 9840 8086 
SD 4365 5170 8409 7109 
Min 231 167 308 167 
Median 4714 5538 6769 6231 
Max 18667 26769 46538 46538 
Table 2. Mean weekly ESA dosage 
In nearly all patients (98.9%) an adjustment of ESA dosage was essential. Relevant changes 
in ESA dosages were defined as an elevation greater than two fold and lowering of a half of 
the ESA dosage, the end of ESA application or the start with more than 4200 U/week.  
The mean value of Hb (measured per patient over the whole study time) was 7.35 mmol/l 
(Table 3). In patients without ESA application during the 12 months study the mean value of 
Hb was larger (7.66 mmol/l) in comparison to patients with ESA dosage (7.27 mmol/l).  
 
 
Dialysis unit 
Total 1 2 3 
Patients   
37 4 7 48 
without ESA Mean Hb N 
Mean 7.63 7.76 7.74 7.66 
SD 0.46 0.61 0.63 0.49 
Min 6.7 6.9 7.2 6.7 
Median 7.5 8.0 7.5 7.5 
Max 8.8 8.3 8.8 8.8 
At least one ESA dosage Mean Hb N 57 31 97 185 
Mean 7.38 7.09 7.25 7.27 
SD 0.41 0.52 0.53 0.50 
Min 6.2 6.0 5.1 5.1 
Median 7.5 7.2 7.4 7.4 
Max 8.6 8.4 8.3 8.6 
Total 
 
 
 
 
mmol/l 
Mean Hb N 94 35 104 233 
Mean 7.48 7.17 7.29 7.35 
SD 0.44 0.57 0.55 0.52 
Min 6.2 6.0 5.1 5.1 
Median 7.5 7.2 7.4 7.4 
Max 8.8 8.4 8.8 8.8 
Table 3. Mean Hb concentrations 
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Table 4 shows the intra-individual variability of hemoglobin (Hbvar): 
 
 
 
Dialysis unit 
Total 1 2 3 
ESA   
37 4 7 48 
without ESA Hb range (min-max) N 
Mean 1.98 1.35 1.93 1.92 
SD 0.92 0.68 1.11 0.93 
at least one ESA dosage Hb range (min-max) N 57 31 97 185 
Mean 2.20 1.74 2.41 2.23 
SD 0.73 0.85 0.88 0.86 
Total Hb range (min-max) N 94 35 104 233 
Mean 2.11 1.70 2.37 2.17 
SD 0.81 0.83 0.90 0.88 
Table 4. Means of haemoglobin variability 
The relation between the treatment mode (HD, olHDF) and ESA dosage as well as Hb is 
shown in the tables 5 and 6: 
 
 
 
Dialysis unit 
Total 1 2 3 
HD All patients  N 40 32 74 146 
Mean 3608 6132 8833 6809 
SD 5058 5511 8313 7293 
Patients with at least one ESA dosage  N 22 28 69 119 
Mean 6560 7009 9473 8354 
SD 5217 5339 8248 7234 
HDF All patients  N 15 . 4 19 
Mean 3515 . 7750 4407 
SD 4160 . 5535 4660 
Patients with at least one ESA dosage  N 9 . 4 13 
Mean 5859 . 7750 6441 
SD 3853 . 5535 4287 
Mixed All patients  N 39 3 26 68 
Mean 3505 3821 10378 6147 
SD 3960 1500 9441 7313 
Patients with at least one ESA dosage  N 26 3 24 53 
Mean 5257 3821 11243 7887 
SD 3775 1500 9314 7410 
Table 5. Relationship between treatment mode and required weekly ESA dosage 
Hb was larger in the olHDF group and the required ESA dosage to reach the Hb 
concentration lower (Hb olHDF 7.56± 0.35 mmol/l, HD 7.25± 0.52 mmol/l, p= 0.01; 
ESA/week olHDF 4407± 4660 U/l, HD 6809±7293 U/l, p= 0.1): Table 6. 
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Dialysis unit 
Total 1 2 3 
Treatment mode   
40 32 74 146 HD Mean Hb [mmol/L] N 
Mean 7.37 7.16 7.23 7.25 
SD 0.43 0.59 0.53 0.52 
HDF Mean Hb [mmol/L] N 15 . 4 19 
Mean 7.58 . 7.50 7.56 
SD 0.38 . 0.25 0.35 
Mixed Mean Hb [mmol/L] N 39 3 26 68 
Mean 7.56 7.22 7.41 7.49 
SD 0.46 0.11 0.61 0.52 
Total Mean Hb [mmol/L] N 94 35 104 233 
Mean 7.48 7.17 7.29 7.35 
SD 0.44 0.57 0.55 0.52 
Table 6. Relationship between treatment mode and Hb value 
In the olHDF group the intraindividual Hbvar was significantly lower than in HD (HD 
0.66±0.28 mmol/l vs olHDF 0.53±0.16 mmol/l, p<= 0.05): Table 7. 
 
 
Dialysis unit 
Total 1 2 3 
HD 
 
 
HDF 
All 
patients 
 
Intra-individual standard deviation of 
the Hb-value 
N 40 32 74 146 
Mean 0.69 0.51 0.71 0.66 
SD 0.29 0.24 0.26 0.28 
All 
patients  
Intra-individual standard deviation of 
the Hb-value 
N 15 . 4 19 
Mean 0.52 . 0.57 0.53 
SD 0.11 . 0.30 0.16 
Table 7. Intra-individual standard deviation of the Hb-values as a function of the treatment 
mode 
In the subanalysis the single pool Kt/V (spkt/V) was >1.2 on average in all centers. But 
there is a significant improvement of spKt/V for olHDF compared to HD (p = 0.04): Table 8: 
 
 
Dialysis unit 
Total 
1 2 3 
HD Mean treatment efficacy (spkt/V) N   
Mean 1.46 1.32 1.55 1.48 
SD 0.60 0.29 0.38 0.44 
HDF Mean treatment efficacy (spkt/V) N 15 . 4 19 
Mean 1.57 . 1.82 1.62 
SD 0.17 . 0.52 0.28 
Mixed Mean treatment efficacy (spkt/V) N 38 3 26 67 
Mean 1.48 1.16 1.45 1.45 
SD 0.24 0.04 0.31 0.27 
Table 8. Single Pool Kt/V as a function of the treatment mode 
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Further analyses regarded the relationship between CRP and albumin. The tables 9 and 10 
show the mean levels of CRP and albumin: 
 
 
Dialysis units 
Total1 2 3 
Mean CRP [mg/l] N 87 33 98 218
Mean 15.82 14.77 13.58 14.65
SD 19.48 8.75 9.67 14.30
Min 3.6 4.5 3.1 3.1
Median 10.2 13.1 10.4 10.6
Max 160 47.6 40.5 160
Table 9. Mean CRP level per dialysis unit and overall   
 
 
Dialysis unit 
Total1 2 3 
Mean albumin [g/l] N 93 35 104 232
Mean 40.28 39.44 38.81 39.49
SD 3.10 2.17 2.84 2.93
Min 30.4 35.8 31.0 30.4
Median 40.5 39.6 39.0 39.6
Max 47.1 43.7 45.9 47.1
Table 10. Mean albumin level per dialysis unit and overall 
For all patients the Hb level was negatively correlated to CRP (r= - 0.24, p< 0.0005) and 
positively to Albumin (r= 0.30, p< 0.0001) and TSAT (r= 0.20, p< 0.005): see table 11: 
 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 
 esamean hbmean 
crpmean 
CRP 
0.08497
0.2115
218
-0.23764
0.0004
218
albmean 
Albumin 
-0.23495
0.0003
232
0.30050
<.0001
232
tsatmean 
TSAT 
-0.12875
0.0497
233
0.19808
0.0024
233
Table 11. Correlation of the total values for CRP, Albumin and TSAT with Hemoglobin 
In a subanalysis we found significantly larger albumin levels and lower CRP concentrations 
in olHDF vs HD (albumin olHDF 40.63+/-2.23 g/l, HD 39.11± 2.76 g/l, p< 0.05; CRP olHDF 
9.96± 8.28 mg/l, HD 16.07 ±  16.26 mg/l, p< 0.05): Tables 12 and 13: 
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Dialysis unit 
Total1 2 3 
Mode   
40 32 74 146HD albumin 
 [g/l] 
N 
Mean 39.89 39.35 38.58 39.11
SD 3.10 2.11 2.72 2.76
HDF albumin 
 [g/l] 
N 14 . 4 18
Mean 40.74 . 40.24 40.63
SD 2.32 . 2.17 2.23
Mixed albumin 
 [g/l] 
N 39 3 26 68
Mean 40.51 40.35 39.24 40.02
SD 3.35 3.06 3.21 3.30
Table 12. Relationship between albumin levels and treatment mode 
 
 
Dialysis unit 
Total1 2 3 
Mode   
39 30 71 140HD CRP 
 [mg/l] 
N 
Mean 18.56 15.52 14.94 16.07
SD 26.70 8.82 10.05 16.26
HDF CRP 
[mg/l] 
N 12 . 2 14
Mean 10.81 . 4.81 9.96
SD 8.68 . 0.22 8.28
Mixed CRP 
 [mg/l] 
N 36 3 25 64
Mean 14.52 7.36 10.43 12.59
SD 10.79 2.55 7.81 9.66
Table 13. Relationship between CRP levels and treatment mode  
4. Discussion 
Our retrospective analysis was performed in three different dialysis centers for 12 months. 
The D1 center had the largest percentage of patients treated with olHDF (olHDF+”mixed”) 
(57 % in D1 vs. 9 % in D2, 29 % in D3).  In D1 the lowest dosage of ESA to reach the Hb 
target was used (Table 2; D1 vs D2 p= 0.003; D1 vs D3 p< 0.0001), the smallest number of D1 
patients were treated with ESA and the time in target was longer than in D2 and D3. In 
addition, it could be demonstrated that in D1 patients the frequency of adaptation of ESA 
dosage and Hbvar were reduced in comparison to the other centers.  
Concerning the ferritin values and the transferrrin saturation (TSAT) there were no 
noticeable differences between the observed centers. But the subanalysis shows a positive 
correlation of the overall TSAT values with the Hb values (p = 0.002, see Table 11) and a 
negative one with the mean ESA consumption (p = 0.05). These results comply with the 
expectation because an improved Hb value is connected with a larger TSAT level and 
reduced ESA needs. 
The treatment efficacy (single pool and equilibrated Kt/V; spKt/V, eKt/V), which was 
measured periodically in the 3 dialysis units, did not show any significant influence on ESA 
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dosage and Hb levels. But the subanalysis calculating the impact of the different treatment 
modes on Kt/V resulted in a significant increased spKt/V for olHDF treatments compared 
with HD (1.62±0.28 for olHDF versus 1.48±0.44 for HD; Table 8).  
Interestingly the correlation analysis also shows a highly significant positive correlation of 
the mean albumin level with the mean Hb values (p < 0.001, Table 11) and a negative one 
with the mean ESA dosage (p = 0.0003). Simultaneously CRP is negatively correlated with 
Hb (p = 0.0004, Table 11). 
The significant difference in albumin concentration most likely played the decisive role for 
ESA dosage and Hb level (Ward, 2005). It is known that in patients who underwent 
convective-diffusive treatment the ESA dosage could be reduced (Vaslaki et al., 2006; 
Bonforte et al., 2002; Eiselt et al., 2000).  That observation was confirmed by our results, 
reaching an economically interesting level of savings in ESA costs: Fig. 1. 
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Fig. 1. Mean Hb level and ESA dosage HD vs. HDF (ESA: p=0.1, ns., Hb: p=0.01) 
Typically, convective diffusive procedures are characterized by an additional removal of 
hydrophobic middle molecules and protein (albumin) bound uremic toxins depending on 
the membrane characteristics (hydrophobic areas, pore size, adsorptive properties, 
biocompatibility) (Ahrenholz et al., 2004; Panicchi et al., 2008). The loss of protein bound 
substances leads to a membrane determined loss of albumin during olHDF sessions 
(Ahrenholz et al., 2004; Samtleben et al., 2003; Combarnous et al., 2002). In low flux dialysis 
protein removal only occurs with adsorptive membranes (PMMA, polyacrilonitrile) with 
decreasing dialysis efficacy for water soluble toxins (Parzer et al., 1993). This removal of 
albumin can be compensated after a time of about 12 weeks in the absence of relevant 
inflammation (Ding et al., 2002; Kaysen et al., 1997). In chronic ambulant peritoneal dialysis 
protein losses are in-between 6 to 10 g/d and albumin losses up to 5 g/d over the peritoneal 
membrane (Kaysen et al., 1984).  
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Mean Albumin HD vs olHDF
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Fig. 2. Mean serum albumin concentration HD vs. olHDF (p=0.01)  
Albumin losses during renal replacement procedures are generally thought of being 
unwanted, as low serum albumin correlates with poor outcome in dialysis patients. 
Therefore, olHDF, that technically spoken is an albumin-loosing therapy, might carry the 
danger of exposing the treated patients to threads associated with low albumin levels. 
It is striking that in our analysis the olHDF group had the largest serum albumin concentration 
(Fig. 2, Table 12). All patients of the “mixed” group (containing patients that had switched 
from HD to olHDF) showed an increase in albumin level rather than a decrease. 
Moreover, olHDF can remove proinflammatory substances such as cytokines (Bellomo et al., 
1991; Lee et al., 2004). Again, we could confirm this phenomenon with lower CRP levels in 
the olHDF group vs. HD group (9.96+/- 8.28 mgl/l vs. HD 16.07+/- 16.26 mg/l, p=0.02), see 
Fig. 3, and Table 13: 
 
Mean CRP Levels HD vs olHDF
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Fig. 3. Mean CRP concentration HD vs. olHDF (p=0.02) 
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Because albumin is a negative acute phase protein we can, in general, expect higher 
concentrations at lower inflammation (Panicchi et al., 2006; Kaysen et al., 1997). However, 
none-biocompatible membranes and partly low flux hemodialysis increases 
proinflammatory cytokines such as TNF-alpha. Ultrapure dialysis fluid is of relevant 
importance to prevent inflammation (Panicchi et al., 2008). On the other hand complement 
activation plays a role for inflammation during the dialysis sessions therefore biocompatible 
membranes are urgently necessary (Hakim et al., 1984). In the olHDF method as use in this 
study, both ultrapure dialysate and biocompatible membrane materials were used, enabling 
clear attenuation of procedure-associated inflammatory processes. This attenuation of 
inflammation to us seems the key factor for increased albumin production that even makes 
up for procedure-associated albumin losses. The nutritional situation (nPCR) has only a 
secondary influence (Savica et al., 2006; Stenvinkel, 2005). Hbvar also depends on 
inflammation and albumin concentration (Brimble et al., 2007). Hbvar in olHDF is lower 
than in HD because of less inflammation and higher concentration of albumin.  
5. Conclusions 
In a retrospective, descriptive, multicentre study the influence of olHDF on Hb Level, ESA 
dosage and Hbvar was evaluated. 233 patients were included in the clinical analysis in three 
dialysis departments (D1 n=94; D2 n= 35, D3 n= 104). Mean dialysis efficacy expressed as 
spkt/V by Daugirdas was comparable in all dialysis units. We found differences in the 
frequency of olHDF in the dialysis departments followed by varying parameters of 
inflammation (CRP) and nutrition (albumin). It can be demonstrated that patients who 
underwent olHDF showed the highest serum albumin levels and the lowest signs of 
inflammation (CRP). This combination leads to significantly higher Hb concentrations and 
surprisingly lower ESA dosages to reach the target Hb in ol HDF vs HD. Due to the reduced 
inflammation Hbvar was improved in olHDF vs HD. There is a correlation between serum 
albumin concentration, Hb level and ESA dosage. OlHDF could be the gold standard for 
prevention of inflammation because of removal of proinflammatory substances and 
hydrophobic and protein bound uremic toxins. OlHDF influences positively inflammation, 
nutrition, Hb level, Hb variability and required ESA dosage in chronic renal replacement 
therapy.  
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